Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)

Current Hepatitis Reports

, Volume 12, Issue 3, pp 149-156

First online:

IL28B Genotype on HCV Infection in Asia

  • Chen-Hua LiuAffiliated withDepartment of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University HospitalHepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University HospitalGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital
  • , Jia-Horng KaoAffiliated withDepartment of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University HospitalHepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University HospitalGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC). Successful HCV eradication can reduce the liver-related mortality and morbidity. Previous studies show that Asian HCV-1 patients tend to have higher sustained virologic response (SVR) rates than Caucasian, Hispanic or African-American HCV-1 patients. Recent genome-wide association studies (GWAS) reveal interleukin-28B (IL28B) genotypes at locus rs12979860 or rs8099917 are strong predictors for SVR in HCV-1 patients treated with peginterferon-α (PEG-IFN-α) plus ribavirin (RBV), and the higher frequencies of favorable IL28B genotype in Asian patients than those in other ethnicity may explain the superior response in Asian HCV-1 patients. However, the predictive role of IL28B genotype is limited for HCV-2 patients and for HCV patients with response-guided therapy. IL28B genotype still predicts SVR in patients with triple therapy by telaprevir (TVR) or boceprevir (BOC). For newer direct-acting antivirals (DAAs), its predictive role remains to be confirmed.

Keywords

Hepatitis C virus Interleukin 28B Asia